BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/1/2014 11:47:00 AM | Browse: 805 | Download: 634
Publication Name World Journal of Diabetes
Manuscript ID 7191
Country Australia
Received
2013-11-08 19:48
Peer-Review Started
2013-11-09 20:44
To Make the First Decision
2014-02-13 16:29
Return for Revision
2014-02-20 09:08
Revised
2014-02-28 14:03
Second Decision
2014-03-18 14:58
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-03-18 15:19
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-04-11 09:53
Publish the Manuscript Online
2014-04-18 11:34
ISSN 1948-9358 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Cardiac & Cardiovascular Systems
Manuscript Type Review
Article Title Origin and therapy for hypertriglyceridaemia in type 2 diabetes
Manuscript Source Invited Manuscript
All Author List Jing Pang, Dick C Chan and Gerald F Watts
Funding Agency and Grant Number
Corresponding Author Gerald F Watts, DSc, MD, PhD, FRACP, FRCP, School of Medicine and Pharmacology, University of Western Australia, GPO Box X2213, Perth, WA 6847, Australia. gerald.watts@uwa.edu.au
Key Words Diabetes; Triglyceride; Therapy
Core Tip Diabetic dyslipidemia relates collectively to hyperglycaemia, insulin resistance, hyperinsulinaemia, abdominal visceral adipose disposition, increased liver fat content, and dysregulated fatty acid metabolism. Insulin resistance in diabetes induces hypertriglyceridaemia by increasing the enterocytic production of chylomicrons and an impaired clearance capacity is also involved. Usual care for diabetic dyslipidemia is statin treatment, but a significant proportion of patients have residual dyslipidemia, related to hypertriglyceridaemia and atherogenic dyslipidemia. Current evidence supports the use of fenofibrate in type 2 diabetics with high triglyceride levels.
Publish Date 2014-04-18 11:34
Citation Pang J, Chan DC, Watts GF. Origin and therapy for hypertriglyceridaemia in type 2 diabetes. World J Diabetes 2014; 5(2): 165-175
URL http://www.wjgnet.com/1948-9358/full/v5/i2/165.htm
DOI http://dx.doi.org/10.4239/wjd.v5.i2.165
Full Article (PDF) WJD-5-165.pdf
Full Article (Word) WJD-5-165.doc
Manuscript File 7191-Review.docx
Answering Reviewers 7191-Answering reviewers.pdf
Copyright License Agreement 7191-Copyright assignment.pdf
Peer-review Report 7191-Peer reviewer(s).pdf
Scientific Editor Work List 7191-Scientific editor work list.doc